ReviewJournal of virology2010
Papillomavirus prophylactic vaccines: established successes, new approaches.
Review in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The contribution of bovines to human health against viral infections.Environmental science and pollution research international · 2021Review
- Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants.Pathogens (Basel, Switzerland) · 2020Article
- Identification of bovine papillomavirus type 1 and 2 from bovine anogenital fibropapillomas.The Journal of veterinary medical science · 2019Article
- Viral Oncology: Molecular Biology and Pathogenesis.Journal of clinical medicine · 2017Review
- Intranasal immunization of pigs with porcine reproductive and respiratory syndrome virus-like particles plus 2', 3'-cGAMP VacciGrade™ adjuvant exacerbates viremia after virus challenge.Virology journal · 2017Article
- Progress and prospects for L2-based human papillomavirus vaccines.Expert review of vaccines · 2016Review
- Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model.The Journal of general virology · 2015Article
- Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus.Journal of clinical medicine · 2015Review
- Development of an IP-Free Biotechnology Platform for Constitutive Production of HPV16 L1 Capsid Protein Using the Pichia pastoris PGK1 Promoter.BioMed research international · 2015Article
- Immunologic treatments for precancerous lesions and uterine cervical cancer.Journal of experimental & clinical cancer research : CR · 2014Review
- Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme.Neuro-oncology · 2014Article
- Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits.Trials in vaccinology · 2014Article
- Optimization of multimeric human papillomavirus L2 vaccines.PloS one · 2013Article
- Targeting human papillomavirus genome replication for antiviral drug discovery.Antiviral therapy · 2013Review
- Emerging human papillomavirus vaccines.Expert opinion on emerging drugs · 2012Review
- Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer.GMS current topics in otorhinolaryngology, head and neck surgery · 2012Article
- Article
- Article
- Article
- A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.